Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 6,194 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Medication Group Clear all

Conditions: DNA Damage, Psychological Stress
Interventions: Propranolol, Placebo oral capsule, Acute stress task, No stress task; Drug · Behavioral
Lead sponsor: Dana Bovbjerg; Other
Eligibility: 20 Years to 59 Years
Enrollment: 239 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Acute Apical Abscess, Pain, Acute
Interventions: Valacyclovir 500 MG, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: General Medical Inpatient Conditions
Interventions: Patient-Centered Transition Intervention; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 65 Years
Enrollment: 513 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Syphilis, Early Syphilis
Interventions: Cefixime 400 milligram Oral Capsule [Suprax], Benzathine Penicillin G; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 10
States / cities: Beverly Hills, California • Los Angeles, California • Oakland, California + 3 more

Conditions: Alopecia, Androgenetic
Interventions: TDM-105795, 0.0025%, TDM-105795, 0.02%, TDM-105795 topical vehicle solution; Drug
Lead sponsor: Technoderma Medicines Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 13
States / cities: North Little Rock, Arkansas • Rolling Meadows, Illinois • Plainfield, Indiana + 10 more

Conditions: Torsades de Pointes
Interventions: VI-0521; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 19 Years to 50 Years
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Epilepsy, Seizure
Interventions: Medilepsy® Chatbot AI-Enhanced, Medilepsy® Chatbot Standard; Other
Lead sponsor: University of Central Florida; Other
Eligibility: 14 Years to 24 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 2
States / cities: Orlando, Florida

Conditions: Chronic Hepatitis C
Interventions: BMS-650032, BMS-790052, BMS-791325, Ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 26
States / cities: Birmingham, Alabama • Coronado, California • Los Angeles, California + 19 more

Conditions: Gonorrhea, Neisseria Gonorrhoeae, Chlamydia Trachomatis
Interventions: Patient delivered partner therapy, Targeted public health partner services; Other · Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 14 Years and older
Enrollment: 33,222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 2
States / cities: Olympia, Washington • Seattle, Washington

Conditions: Chronic Pulmonary Disorder
Interventions: breathing techniques, Self-Administered Baseline and Transition Dyspnea Indexes; Other · Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 19 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Usual care American Society of Plastic Surgeons booklet "Breast Reconstruction", Decision tool, Usual Care Group - Outcome Measures, Decision Group - Outcome Measures, Demographic and Background Questions; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Opioid Use Disorder
Interventions: Patient Decision Aid; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Tarzana, California

Conditions: Post-traumatic Stress Disorder, Generalized Anxiety Disorder, Panic Disorder, Social Anxiety Disorder
Interventions: Cognitive-behavioral therapy, Psychotropic medication optimization, Treatment as Usual; Behavioral · Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 75 Years
Enrollment: 1,004 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 4
States / cities: Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 1 more

Conditions: Drug-resistant Epilepsy, Focal-Onset Seizures
Interventions: Padsevonil, Placebo; Drug · Other
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 18 Years and older
Enrollment: 411 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 27
States / cities: Chandler, Arizona • Little Rock, Arkansas • La Jolla, California + 21 more

Conditions: Angina Pectoris
Interventions: Osteopathic manipulation; Procedure
Lead sponsor: University of New England; Other
Eligibility: 18 Years to 81 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Saco, Maine

Conditions: Radiocontrast Nephropathy
Interventions: N-Acetylcysteine (NAC), 0.9% Sodium-chloride; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Anemia
Interventions: Venofer; Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 12 Years to 16 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Norristown, Pennsylvania

Conditions: Aging, Preventive Care, Multimorbidity, Palliative Care
Interventions: Annual Wellness Visit, Annual Wellness Visits + Geriatric Resources and Assessment for the Care of Elders (AWV + GRACE); Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 7,140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 4
States / cities: Derby, Connecticut • Boston, Massachusetts • Winston-Salem, North Carolina + 1 more

Conditions: Post Traumatic Stress Disorder (PTSD), Addiction, Alcohol Abuse
Interventions: N-Acetylcysteine (NAC) Treatment, Cognitive Behavioral Therapy (CBT), Inactive Placebo Oral Capsule, Functional magnetic resonance imaging (fMRI), Proton magnetic resonance spectroscopy (MRS) Imaging; Drug · Behavioral · Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 70 Years
Enrollment: 182 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 2
States / cities: Charleston, South Carolina

Conditions: Asthma
Interventions: Coping Peer Support, Doctor Asthma Messages, Coping Peer Asthma Messages, Asthma Supervision, Music Tracks; Behavioral
Lead sponsor: Rush University Medical Center; Other
Eligibility: 11 Years to 16 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Amblyopia, Amblyopia Unilateral, Amblyopia, Anisometropic, Amblyopia Strabismic
Interventions: Valproate, Placebo, Patch; Drug · Behavioral
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 8 Years to 17 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Artificial Intelligence (AI), Clinical Reasoning, Clinical Decision-making, Medical Education
Interventions: Workshop-First; Other
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Palo Alto, California • Orlando, Florida • Boston, Massachusetts + 1 more

Conditions: Graft-versus-host Disease (GVHD)
Interventions: Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 38
States / cities: Tucson, Arizona • Duarte, California • La Jolla, California + 28 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Exenatide SC, Exenatide IV, Placebo SC, Exendin-9, Placebo IV; Drug
Lead sponsor: Carl T. Hayden VA Medical Center; Federal
Eligibility: 35 Years to 70 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Phoenix, Arizona

Search by objective public record fields.

Brief Stresses Experimental Study

Valacyclovir in Pain Management of Acute Apical Abscesses

IMPaCT (Individualized Management Towards Patient-Centered Targets)

Cefixime for Alternative Syphilis Treatment

Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia

A Study to Evaluate How VI-0521 Affect Cardiac Repolarization in Healthy Male and Female Volunteers

AI-Based Mobile Intervention on Medication Non-Adherence and Transition

Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications

Washington State Community Expedited Partner Treatment (EPT) Trial

Breath Training Exercise for the Reduction of Chronic Dyspnea

Optimizing Decision Making About Breast Reconstruction After Mastectomy: A Patient-Centered Approach

Pilot Test of Patient Decision Aid for Opioid Use Disorder

Primary Care Intervention Strategy for Anxiety Disorders

Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy

Study of Osteopathic Manipulation in the Management of Angina

N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients

Iron Sucrose in Non-Dialysis Dependent (NDD-CKD) Pediatric Patients

Annual Wellness Visits vs GRACE-augmented Annual Wellness Visits For Older Adults With High Needs - Phase 2

Clinical Trial for Alcohol Use Disorder and Post Traumatic Stress Disorder (PTSD)

Coping Peer Intervention for Adherence

Valproate for the Treatment of Residual Amblyopia

Teaching Doctors in Training to Reason With Artificial Intelligence

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes